Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials

  • Gary T. Ferguson (Creator)
  • Nicola Brown (Creator)
  • Chris Compton (Creator)
  • Thomas C. Corbridge (GlaxoSmithKline) (Creator)
  • Kelly Dorais (Creator)
  • Charles Fogarty (Creator)
  • Catherine Harvey (Creator)
  • Morrys C. Kaisermann (Contributor)
  • David Lipson (Creator)
  • Neil Martin (Creator)
  • Frank C. Sciurba (Creator)
  • Marjorie Stiegler (Creator)
  • Chang-Qing Zhu (Creator)
  • D. Bernstein (Creator)

Dataset

Description

Abstract Background The comparative efficacy of inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist (ICS/LAMA/LABA) triple therapy administered via single or multiple inhalers in patients with chronic obstructive pulmonary disease (COPD) has not been evaluated comprehensively. We conducted two replicate trials comparing single- with multiple-inhaler ICS/LAMA/LABA combination in COPD. Methods 207608 and 207609 were Phase IV, 12-week, randomized, double-blind, triple-dummy non-inferiority trials comparing once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg via Ellipta inhaler, with twice-daily budesonide/formoterol (BUD/FOR) 400/12 μg via metered-dose inhaler plus once-daily tiotropium (TIO) 18 μg via HandiHaler. Patients had symptomatic COPD and forced expiratory volume in 1 s (FEV1)
Date made available2020
Publisherfigshare

Cite this